Chemed (CHE) Form 144: Insider Plans Sale of 150 Shares (69,567)
Chemed Corporation (CHE) Form 144 disclosure: A notice was filed reporting a proposed sale of 150 shares of the issuer's capital stock through J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Chemed Corporation (CHE) Form 144 disclosure: A notice was filed reporting a proposed sale of 150 shares of the issuer's capital stock through J.P. Morgan Securities LLC on the NYSE, with an approximate sale date of 09/09/2025 and an aggregate market value of 69,567. The shares were acquired on 05/29/2025 as executive compensation from the issuer; the filing shows 277 shares were originally acquired on that date and payment was made on 05/29/2025. The filer reports 14,571,695 shares outstanding for the class. No securities were reported sold by the person in the past three months in this filing.
Positive
- Required insider sale disclosure provided, including broker, number of shares, and planned sale date
- Acquisition source and payment details are documented: shares were received as executive compensation on 05/29/2025
Negative
- None.
Insights
TL;DR: Routine Form 144 disclosing an executive's planned sale of 150 shares; informational rather than material.
The filing simply notifies the market that an individual who received 277 shares as executive compensation on 05/29/2025 intends to sell 150 shares via J.P. Morgan on 09/09/2025. The document contains no earnings, guidance, or operational details—only required transaction disclosure. For investors, this is a compliance-level disclosure that signals a planned insider sale but provides no new information about company performance.
TL;DR: Compliance-focused disclosure showing an insider sale tied to executive compensation; no governance concerns evident from the form alone.
The filer certifies the absence of undisclosed material adverse information and records the sale plan details as required by Rule 144. The form notes the securities were received as executive compensation and that there were no securities sold in the past three months by the person. As filed, the notice is a standard transparency measure; it does not indicate any improper conduct or governance action beyond routine insider selling disclosure.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did the Chemed Corporation (CHE) Form 144 disclose?
Which broker and exchange are named in the proposed sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.